Postmarketing Observational Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
Phase of Trial: Phase IV
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms ADAPT
- Sponsors AbbVie
- 09 Mar 2018 Planned End Date changed from 30 Sep 2019 to 1 Dec 2019.
- 09 Mar 2018 Planned primary completion date changed from 30 Sep 2019 to 1 Dec 2019.
- 05 Oct 2017 Status changed from not yet recruiting to recruiting.